<DOC>
	<DOCNO>NCT00645255</DOCNO>
	<brief_summary>The study design evaluate long term efficacy safety Meridia 15 mg daily obese subject .</brief_summary>
	<brief_title>Study Examine Longer-Term Efficacy Safety Sibutramine Hydrochloride Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Sibutramine</mesh_term>
	<criteria>The subject must able communicate meaningfully investigator , legally competent , provide write informed consent , follow specify diet exercise program . Female subject must nonlactating must either ) least one year postmenopausal ; b ) surgically sterilize bilateral tubal ligation , bilateral oophorectomy hysterectomy ; c ) use adequate contraceptive precaution ( i.e. , oral contraceptive , approve hormonal implant , intrauterine device , diaphragm spermicide , condom spermicide ) . A serum pregnancy test , must negative , require female except surgically sterile postmenopausal . The subject must least 18 year old . The subject must systolic blood pressure &lt; =140 mmHg , diastolic blood pressure &lt; =90 mmHg , pulse rate &lt; =95 beat per minute ( see Section VI.I. ) . Treated hypertensive allow study . The subject must enrol nonpharmacologic weight loss program document weight loss &gt; =10 kg maintain least 6 month , gain back &lt; 50 % peak lose weight ( currently maintain weight loss &gt; =10 kg ) , stabilize weightmaintaining diet least 1 month prior screen . The subject 's body mass index ( BMI ) must &gt; =27 kg/m2 &lt; =40 kg/mg2 , round near whole unit , must &gt; =30 kg/m2 prior initiation nonpharmacological weight loss program prior screen . The subject must live immediate geographic area least 2 year prior screen . If subject chronic medication , dose must constant least two month prior screen . The subject must history anorexia nervosa . The subject must history clinically significant cardiac disease , clinically significant abnormal cardiac condition , know clinically significantly abnormal ECG . Specifically excluded condition include coronary artery disease , clinically significant cardiac arrhythmia , congestive heart failure . The subject must history stroke . The subject must history narrow angle glaucoma . The subject must organic cause obesity ( e.g. , untreated hypothyroidism ) . The subject must history seizure . The subject must severe renal hepatic dysfunction . The subject must use follow medication take study medication : monoamine oxidase inhibitor ( e.g. , furazolidone , phenelzine , procarbazine HCl , selegiline ) , lithium , serotonin reuptake inhibitor , opioids ( e.g. , dextromethorphan , meperidine , pentazocine , fentanyl ) , prescribe overthecounter weight loss agent , centrally act appetite suppressant , tryptophan , migraine agent ( e.g. , sumatriptan succinate , dihydroergotamine ) medication , opinion Investigator , may pose harm subject , obscure effect study medication interfere process drug absorption , distribution , metabolism , excretion ( i.e. , enzyme inducer enzyme inhibitor ) . The regular use sympathomimetics ( e.g . cough cold remedy , asthma medication ) contraindicate study . Study medication discontinue 3 day use opioids . THE SUBJECT SHOULD NOT BE TAKEN OFF ANTIDEPRESSANTS IN ORDER TO BE PLACED IN THE STUDY . The subject must history hypersensitivity MERIDIA . The subject must history alcohol drug addiction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>